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Abstract
Background: We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP)
could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemotherapy in
the model of spontaneously metastasizing 4T1 mouse mammary gland tumors. In the present study, we aimed to
investigate whether the previously observed activity of pyridine compounds pertains also to the prevention and the
treatment of metastatic prostate tumors, in a combined chemotherapy with docetaxel.
Methods: Cancer-preventing activity of 1,4-DMP was studied in the model of prostate tumors spontaneously arising in
C57BL/6-Tg (TRAMP)8247Ng/J (TRAMP) mice. The efficacy of the combined chemotherapy, comprising simultaneous use
of 1,4-DMP and docetaxel, was evaluated in the orthotopic mouse model of human PC-3M-luc2 prostate cancer. The
toxicity of the applied treatment was also determined.
Results: The development of prostate tumors in TRAMP mice remained unaffected after administration of 1,4-DMP.
Similarly, no effect of 1,4-DMP was found on the growth of orthotopically transplanted PC-3M-luc2 tumors. However,
when 1,4-DMP was administered along with docetaxel, it enhanced the anticancer activity of the chemotherapy. As a
result, in PC-3M-luc2-bearing mice statistically significant inhibition of the tumor growth and lower metastases incidence
were observed. The decreased metastatic yield is probably related to the diminished platelet activity observed in mice
treated with combined therapeutic regimen. Finally, the combined treatment exhibited lowered side effects
accompanying docetaxel administration.
Conclusions: Results presented herein confirm previously published data on the anticancer activity of pyridine
compounds and demonstrate that 1,4-DMP may be beneficially implemented into chemotherapy utilizing various
cytotoxic agents, directed against multiple metastatic tumor types.
Keywords: Prostate cancer, Metastasis, Prevention, Combined therapy, 1-methylnicotinamide, 1,4-dimethylpyridine,
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Background
Prostate cancer is the second most common cancer of
men, affecting approximately 14% of patients [1]. While the
risk of developing prostate cancer might be beneficially in-
fluenced by proper diet and physical activity [2], there are
no confirmed pharmacological means for the prevention of
these types of tumors. The majority of prostate cancer cases
are diagnosed at the localized stage enabling effective treat-
ment; however, a significant fraction of patients develops
metastatic disease that often progresses into treatment-
irresponsive, ultimately resulting in patient’s death [3].
Initial treatment of prostate cancer usually comprises
hormone therapy; however, when tumors are irrespon-
sive to hormonal treatment (i.e., in case of castrate-
resistant prostate cancer), the most common first-line
treatment includes the simultaneous use of docetaxel
and prednisone. Docetaxel is a semi-synthetic taxane
that inhibits microtubular depolymerization and block
bcl-2 and bcl-xl gene expression [4, 5]. Prednisone, in
turn, is a glucocorticoid that is used to improve symp-
toms such as pain [6]. It was also shown to inhibit cell
proliferation and induce apoptosis in prostate cancer
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cells [7, 8], and thus decrease the level of prostate-
specific antigen [9]. Accordingly, in multiple studies,
prednisone was shown to promote anticancer activity
of docetaxel [10–14]. However, the use of glucocorti-
costeroids in patients with prostate cancer is associated
with the risk of adverse side effects (as reviewed, for ex-
ample, by Dorff and Crowford [15]), and it eventually
leads to the development of resistance to chemotherapy
[16]. Therefore, there is still an urgent need for new
treatment regimens that would enable efficient yet safe
means for the therapy of patients suffering from pros-
tate cancer.
1-methylnicotinamide (1-MNA) is an endogenous me-
tabolite of nicotinamide (NA) that has recently gained
attention due to its anti-inflammatory [17] and anti-
thrombotic [18] activity driven by mechanisms dependent
on prostacyclin (PGI2) release [18, 19]. Another
compound that has been shown to modulate thrombus
formation based on the PGI2-related mechanisms is 1,4-
dimethylpyridine (1,4-DMP) – a structural analog of 1-
MNA that arises naturally in roasted coffee seeds [20]. In
addition, it has been recently shown that both 1-MNA
and 1,4-DMP could inhibit metastases formation in the
model of experimental and spontaneous metastasis of 4T1
murine mammary gland cancer [21].
The present work is aimed to establish whether 1,4-
DMP may have an anti-oncogenic effect in the prophy-
laxis and the treatment of prostate tumors.
Methods
Drugs
1,4-DMP and 1-MNA were used in the form of chlorides
provided by the Institute of Applied Radiation Chemistry,
Technical University of Lodz, Poland. Prior to use, both
salts were diluted in drinking water such that mice re-
ceived the predetermined dose of the drugs. Docetaxel
(DTX) was purchased at Ak Scientific (USA). All drugs
were administrated at the doses and according to the
schedules presented in Table 1.
Mice
Eight- to twelve-weeks-old male C57BL/6-Tg(TRAMP)
8247 Ng/J (TRAMP) mice were purchased from the
Jackson Laboratory (USA). Seven- to eight-weeks-old
BALB/c Nude male mice were provided by Charles Riv-
ers Laboratories (Germany) (Table 2). All experiments
were performed according to the Interdisciplinary Prin-
ciples and Guidelines for the Use of Animals in Research,
Marketing and Education issued by the New York Acad-
emy of Sciences’ Ad Hoc Committee on Animal Re-
search and were approved by the 1st Local Committee
for Experiments with the Use of Laboratory Animals,
Wroclaw, Poland.
Cell culture and transplantation
Human prostate cancer PC-3M-luc2 cell line stably ex-
pressing the firefly luciferase gene (luc) was obtained
from Caliper Life Sciences Inc. (USA). Cells were cul-
tured in RPMI 1640 + Gluta-MAX™ medium (Life Tech-
nologies, USA) supplemented with 10% fetal bovine
serum (Sigma-Aldrich, Germany) and antibiotics (peni-
cillin and streptomycin—Polfa Tarchomin, Poland). Cell
line cultures were maintained at 37 °C in a humidified
atmosphere with 5% CO2.
Prior to the transplantation, cells were trypsinized
(IIET, Poland), centrifuged (200 × g, 4 °C, 5 min) and
counted. Then, cells were resuspended in Hank’s Bal-
anced Salt Solution (HBSS; IIET, Poland).
Male BALB/c Nude mice were intraperitoneally injected
with ketamine at a dose of 50 mg/kg (VET-AGRO Sp. z
o.o., Poland) and anesthetized with the mixture of air and
isoflurane (3% v/v). 1.0 cm wide abdominal wall incision
was made just above the bladder, in the lower part of ab-
domen, and the prostate gland was exposed for the injec-
tion. Then, 5 × 106 PC-3M-luc2 cells in 0.05 ml of HBSS
were inoculated into the dorsal prostate lobes of mice. Im-
mediately after the transplantation, incised abdominal wall
and skin were sewed with soluble surgical suture.
Estimation of the antitumor activity
The development of prostate tumors in TRAMP mice
was monitored weekly by physical examination. Adeno-
carcinoma formation was confirmed by histological
examination of the tumors isolated from mice during
necropsy carried out in animals with clear physiological
(e.g., body weight or body temperature decrease, body
posture, ruffled fur) and behavioral symptoms (e.g., de-
creased movement) of an advanced disease. Briefly,
Table 1 Drugs, doses and therapeutic regimens applied in the presented studies
Experimental model Drug Route of administration Dose Treatment regimen
Spontaneous tumor
formation (Fig. 1)
1-MNA per os in drinking water 100 mg/kg/day continuously from the age of 8 to 12 weeks
to the day of the necropsy
1,4-DMP per os in drinking water 100 mg/kg/day continuously from the age of 8 to 12 weeks
to the day of the necropsy
PC-3 M-luc2 tumors
(Fig. 2)
1,4-DMP per os in drinking water 100 mg/kg/day continuously from the day 1 to the end
of the experiment
DTX intraperitoneally 10 mg/kg 2 doses at days 15 and 22
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prostate tumors were isolated and fixed in buffered for-
malin, and then cut into 4-μm-thick sections that were
subsequently dewaxed with xylene. Following rehydra-
tion in a gradient of ethanol, the sections were washed
in distilled water, cytoplasm was stained with eosin while
nuclei were counterstained in hematoxylin. Finally, the
preparations were dehydrated in an alcohol gradient and
coverslip mounted. The histological appearance of the
tissue was examined at 50× or 100× magnitude.
Using an In vivo MS FX PRO system (Carestream
Health INC., USA), in vivo visualizations of PC-3 M-
luc2 tumors growing in prostate gland of BALB/c Nude
mice were performed no more often than every 4 days
starting from the 15th day of the experiment. In brief,
about 10 min before imaging, D-luciferin potassium salt
(Synchem INC., Germany) was administered to each
mouse intraperitoneally at a dose of 150 mg/kg. Then,
animals were anesthetized with a 3–5% (v/v) mixture of
isoflurane (Forane, Abbott Laboratories, USA) in syn-
thetic air (200 ml/min). Anesthesia was maintained with
1.5–2% (v/v) mixture of isoflurane and synthetic air de-
livered via individual masks. Visualization was carried
out using the following settings: for X-ray — t = 2 min,
f-stop = 5.57, FOV = 198.6; for luminescence capture — t
= 3 min, binning 2 × 2, f-stop = 5.57, FOV = 198.6. Im-
ages were analyzed with Carestream MI SE software
(Carestream Health INC., USA). The intensity of the lu-
minescent signal is presented as the sum intensity of the
region of interest and expressed in arbitrary units (a.u.).
Tumor tissue was also excised and weighted on the last
day of the experiment (day 46).
Evaluation of the antimetastatic effect
Livers, lungs, kidneys, bones and axillary as well as in-
guinal lymph nodes were isolated and fixed in buffered
formalin on the day of the necropsy, in order to detect
metastases in the mice bearing prostate tumors. Then,
tissue samples were cut into 4-μm-thick sections and
stained as described hereinabove. The number of metas-
tases in isolated tissues was counted at 50× or 400×
magnitude.
Platelet activation status
Blood samples were collected on days 87, 122, 213 and
during animal’s necropsy in the model of the spontan-
eously formed prostate tumors or on the last day of the
experiment (day 46) in case of mice bearing PC-3M-luc2
tumors. Samples were collected in tubes containing
0.05 ml of 5% ethylenediaminetetraacetic acid (EDTA)
solution (Sigma-Aldrich, Germany). Platelet-related
morphology analyzes were performed using Mythic 18
analyzer (C2 Diagnostics, France). Then, blood plasma
was obtained by centrifugation (2000 × g, 15 min, 4 °C)
and stored at −80 °C until further analyzes. Prostacyclin
generation in the treated mice was determined by the
quantification of plasma 6-keto-prostaglandin F1α (6-
keto-PGF1α) levels. Based on thromboxane B2 (TXB2),
von Willebrand factor (vWF) and soluble P-selectin
plasma concentrations, platelet activation status was es-
timated. Using commercial kits available from Cusabio
Biotech Co. Ltd. (Wuhan, China), all analyzes were con-
ducted via the ELISA technique. In addition, plasma
concentration of transforming growth factor β1 (TGF-
β1) was determined with ELISA kit from Boster Bio-
logical Technology (USA). All ELISA-based analyzes
were conducted according to the manufacturer’s
instructions.
Protein expression in tumor tissue
Protein expression in prostate tumor tissue was analyzed
according to the standard Western blot procedure [22].
In brief, using a FastPrep®-24 MP Bio device (Mp Bio-
medicals LLC., USA), samples of tumor tissue that were
collected and immediately frozen on the last day of the
experiments were homogenized in RIPA Buffer (Sigma-
Aldrich, Germany) with the following settings: CP 24 ×
2, 6 m/s, 40 s. According to the manufacturer’s protocol,
protein content in all samples was analyzed using a Bio-
Rad Protein Assay (Bio-Rad Laboratories Inc., USA).
Samples containing 100 μg of protein were separated on
the pre-cast 4–20% gradient gels (Bio-Rad Laboratories,
Inc., USA) and transferred onto 0.45 μm polyvinylidene
fluoride (PVDF) membranes (Merck Millipore, USA).
Next, the membranes were probed with primary rabbit
polyclonal anti-E-cadherin (1:1000), anti-N-cadherin
(1:1000), anti-VEGFR-1 (1:200) antibodies (all from Pro-
teintech Group, USA) or mouse anti-β-actin (1:1000,
Sigma-Aldrich, Germany) antibody. Finally, according to
the manufacturer’s instruction, the analyzed proteins
were detected with IRDye® 800CW Goat anti-Rabbit IgG
or IRDye® 680RD Donkey anti-Mouse IgG (both from
LI-COR, USA). Blots were visualized in ODDYSEY® CLx
Imager (LI-COR, USA) and analyzed with ImageJ Soft-
ware as follows. The total E-cadherin cellular content
comprising truncated and unprocessed E-cadherin (with
a molecular weight of approximately 100 and 130 kDa,
respectively) was calculated. Similarly, total N-cadherin
cellular content comprising mature and unprocessed N-
cadherin (with a molecular weight of approximately 70
and 100 kDa, respectively) was determined. Then, E-
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cadherin and N-cadherin contents were normalized to
β-actin. Finally, E-cadherin to N-cadherin ratios in indi-
vidual samples were calculated and presented as mean ±
SD values.
Toxicity of the anticancer treatment
The toxicity of the proposed anticancer treatment strat-
egy and its influence on the overall health condition
were estimated based on body weight changes as well as
morphological and biochemical blood analyzes. The
body weight of experimental animals was measured
thrice each week throughout the course of all studies.
Blood morphology was performed with Mythic 18
analyzer (C2 Diagnostics, France). Using reagents and
procedures provided by the manufacturer, biochemical
analyzes were performed in Cobas C 111 analyzer
(Roche Diagnostics, Switzerland).
Statistical analysis
Data normality was estimated using the Shapiro-Wilk
test with a predetermined value of p < 0.05. The Tukey-
Kramer multiple comparison test for parametric data or
the Kruskal–Wallis Test for non-parametric data was
applied; p values lower than 0.05 were considered sig-
nificant. All calculations were performed using Graph-
Pad Prism 7 (GraphPad Software, Inc., USA) software.
Unless stated otherwise, all data presented on graphs
correspond to mean ± SD values.
Results
The influence of 1,4-DMP on the onset and metastasis of
spontaneously formed prostate tumors
To establish whether 1,4-DMP might prevent the devel-
opment of prostate tumors, the compound was con-
tinuously given to male TRAMP mice that during their
life span spontaneously develop mild intraepithelial
hyperplasia to malignant neoplasia within prostate
gland. For comparative purposes, another group of the
animals was treated with 1-MNA, a primary analog of
1,4-DMP that was proven to possess significant anti-
thrombotic and anti-inflammatory activity. 1-MNA,
and to a lesser extent also 1,4-DMP, delayed the onset
of prostate lesions in TRAMP mice (Fig. 1a). However,
none of the given compounds prolonged the life span
of treated animals (Fig. 1b). Histopathological analysis
of the tumor tissues excised during the necropsy con-
firmed the development of malignant adenocarcinomas
in approximately 80% of the mice in all experimental
groups (Fig. 1c and d).
Histopathological analysis demonstrated that metas-
tases in TRAMP mice prostate adenocarcinomas were
developed in lymph nodes, lungs, liver and kidneys
(Fig. 1d). Metastatic lesions were diagnosed in around
30% of untreated animals. Similarly, metastases were
found in 30% of animals treated with 1,4-DMP. In
contrast, when treated with 1-MNA, 50% of mice de-
veloped metastases (Fig. 1c, not statistically significant
difference).
The analysis of morphological features of blood
platelets did not reveal changes in platelet mean vol-
ume and platelet distribution width (PDW) occurring
during the study; however, we noted an increase in
platelet count and decreased level of PDW in animals
during the necropsy (Additional File: Figure S1c). The
treatment either with 1-MNA or 1,4-DMP did not
affect the platelet morphological parameters (Fig. 1e–
g, Additional File 1: Figure S1a-c). Similarly to plate-
lets, red blood cell parameters also remained un-
affected by the tumor progression, with an exception
of the time preceding necropsy where a significant
drop in red blood count was observed in all experi-
mental groups. However, none of the studied com-
pounds influenced the red blood cell parameters
(Additional File 1: Figure S1d).
While there was no obvious change in the white
blood cell count in TRAMP mice developing prostate
tumors that was observed in the course of the study,
we observed that 1,4-DMP and to a lesser extent 1-
MNA tended to decrease the number of all of lympho-
cytes, monocytes and granulocytes in the treated
animals, when compared to the control group
(Fig. 1h–j, Additional File 1: Figure S1e–g). This effect
might be attributed to prostacyclin-dependent splenic
dilation in the treated mice that leads to white blood
cells pooling in the spleen, and in consequence, a sys-
temic decrease in the white blood cell count [23]. The
analysis of the biochemical parameters of platelet ac-
tivity revealed no effect of the studied compounds on
platelet activity in TRAMP mice (Fig. 1l–o). Finally, dur-
ing the tumor development process, we observed that in
TRAMP mice, the plasma level of TGF-β1 was not af-
fected either by 1,4-DMP or by 1-MNA (Additional File 1:
Figure S1h).
Anticancer activity of the combined treatment of prostate
cancer comprising simultaneous application of 1,4-DMP
and docetaxel
The growth of primary tumors localized in prostate glands
of BALB/c Nude mice was monitored throughout the ex-
periment by in vivo imaging of the luminescence generated
by PC-3M-luc2 cells. The analysis of the luminescence in-
tensity indicated that 1,4-DMP when administered alone
did not inhibit the growth of PC-3M-luc2 prostate tumors.
On the contrary, marked tumor growth inhibition was ob-
served when mice were treated with docetaxel alone or ad-
ministered with 1,4-DMP (Fig. 2a and b). These
observations were confirmed by the analysis of the tumor
mass isolated from the mice on day 46 of the experiment.
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Docetaxel, when administered alone, inhibited the growth
of PC-3M-luc2 tumors in around 50% when compared to
the control group of animals (0.40 g vs. 0.81 g, respectively).
Antitumor activity of docetaxel was additionally enhanced
when the drug was administrated with 1,4-DMP and
reached approx. 80% tumor growth inhibition (0.17 g vs.
0.81 g, p < 0.05) (Fig. 2c).
Histopathological analysis of tissues collected from mice
led to the identification of PC-3M-luc2 metastatic lesions
in such tissues as lymph nodes, liver and lungs (Fig. 2d).
We observed that the frequency of metastases formation in
mice treated with 1,4-DMP decreased by almost 50%.
Similarly, the number of metastases-bearing animals de-
creased in case of single-drug treatment with docetaxel.
Most interestingly, none of the mice treated with 1,4-DMP
and docetaxel developed PC-3M-luc2 metastases during
the study (see Table 3).
We also decided to investigate the influence of ap-
plied treatment on the metastatic potential of tumor-
forming cancer cells. To this end, we evaluated the
expression of E-cadherin, N-cadherin and vascular
endothelial growth factor receptor 1 (VEGFR1) in
tumor tissue. The results of the Western blot analysis
show that 1,4-DMP had no significant effect on E-
Fig. 1 The influence of 1,4-DMP and 1-MNA on the development and the progression of prostate cancer. a The onset of the prostate gland le-
sions; b survival of the TRAMP mice continuously treated with 1-MNA and 1,4-DMP. c Summarized results of the frequency of the neoplasia,
adenocarcinomas and metastases in TRAMP mice determined by the means of histopathological analysis of the tissues isolated during the nec-
ropsy. d Images of primary tumors (neoplasia and adenocarcinomas) identified in non-treated and drug-receiving animals and of the metastases
localized in lungs of the control animals, kidney of the animal treated with 1-MNA, or liver of the mouse receiving 1,4-DMP. Results of the mor-
phological analysis carried out on blood samples collected during the necropsy of the animals: e platelet count; f mean platelet volume (MPV); g
platelet distribution width (PDW); h lymphocyte count; i monocyte count; and j granulocyte count. Plasma concentrations of k TXB2, l 6-keto-
PGF1α, m vWF, n soluble P-selectin determined by ELISA. All data are presented as mean ± SD
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cadherin to N-cadherin expression ratio. In contrast,
when mice were treated with docetaxel given alone,
over twofold increase in E-cadherin to N-cadherin ex-
pression ratio was observed (not statistically signifi-
cant). Such a phenomenon was additionally enhanced
by simultaneous application of 1,4-DMP that allowed
to reach over threefold enhancement of E-cadherin to
N-cadherin expression ratio (Fig. 2f ). In addition, in
PC-3M-luc2 tumor-bearing mice, we have observed
the appearance of low molecular weight fragments of
E-cadherin (40 kDa). The concentration of these pro-
tein fragments was lowered in both groups treated
with docetaxel, given either alone or with 1,4-DMP,
while it was unaltered in mice receiving 1,4-DMP
alone (Fig. 2g). The expression of VEGFR-1 was
Fig. 2 Anticancer activity of the combined treatment comprising the use of docetaxel (DTX) and 1,4-DMP in the model of human prostate
cancer PC-3M-luc2 xenografted into prostate glands of BALB/c Nude mice. a Results of in vivo imaging of PC-3M-luc2 tumors performed on day
41 of the experiment. b Kinetics of the PC-3M-luc2 tumor growth in mice treated with docetaxel (DTX) and 1,4-DMP given either alone and in a
comparison to the control group of animals. Days of drug administration are indicated with gray arrows for docetaxel (DTX) and dotted arrow for
1,4-DMP. c PC-3M-luc2 tumor weight measured on the last day of the experiment (day 46) (*p < 0.05 vs. control and 1,4-DMP). d Images of metas-
tases localized in liver of the control animal, lymph node of docetaxel (DTX)-treated mouse and lungs of the 1,4-DMP-treated mouse (from left to
right). e Images of bands obtained during Western blot analysis of protein expression in tumor tissue of (I) control animals and animals treated
with (II) docetaxel (DTX), (III) 1,4-DMP and (IV) docetaxel (DTX) with 1,4-DMP. f E-cadherin : N-cadherin expression ratios in the samples of tumor
tissue collected on the last day of the experiment. The total cellular content of E-cadherin (comprising protein characterized by the molecular
weight of 130 and 100 kDa) and N-cadherin (comprising protein characterized by the molecular weight of 100 and 70 kDa) was first normalized
to the content of β-actin and then used to determine E-cadherin to N-cadherin expression ratios. g The level of low molecular weight fragment
of E-cadherin in PC-3M-luc2 tumors normalized to the content of β-actin. h The expression of VEGFR-1 in PC-3M-luc2 tumors normalized to the
content of β-actin. i Plasma concentration of TGF-β1 in mice bearing PC-3M-luc2 tumors. All data are presented as mean ± SD values
Table 3 Frequency of metastases formation and localization of
new lesions in mice bearing PC-3M-luc2 tumors
Treatment Animals with metastases/all
animals tested
Metastases location
Control 7/9 Lungs, liver, lymph
nodes
1,4-DMP 4/9 Lungs, liver
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decreased in about 30% in mice treated with com-
bined therapy but was not affected either by docetaxel
or by 1,4-DMP given alone (Fig. 2h).
Increased E-cadherin to N-cadherin expression ratio
was accompanied by the decreased plasma concentra-
tion of TGFβ-1 in mice receiving the combined treat-
ment consisting of docetaxel and 1,4-DMP (20.5 ±
5.1 ng/ml vs. 28.13 ± 3.7 ng/ml in the control group of
mice, Fig. 2i).
The analysis of the morphological parameters of
blood platelets revealed that while docetaxel given
alone slightly lowered the platelet count, 1,4-DMP did
not influence the platelet number when given alone
but restored the number in docetaxel-treated animals
(Fig. 3a and b). In addition, we observed that in ani-
mals receiving 1,4-DMP together with docetaxel, the
mean platelet volume (MPV) and PDW were lowered
when compared to the untreated animals (6.02 ± 0.4
and 36.6 ± 4.8 vs. 6.42 ± 0.4 and 40.19 ± 5.2 fL in the
control group of animals, Fig. 3c and d). In addition,
when analyzing biochemical parameters of platelet
activity, we observed that both docetaxel given alone
as well as administered with 1,4-DMP significantly
reduced plasma concentrations of TXB2 (49.18 ±
24.0 pg/ml, 36.55 ± 19.6 pg/ml, respectively, vs. 147.4
± 43.1 pg/ml in the control, p < 0.05), soluble P-
selectin (158.3 ± 46.3 ng/ml, 157.6 ± 36.7 ng/ml,
respectively, vs. 256 ± 53.9 ng/ml in the control, p <
0.05), and vWF (2479 ± 764 ng/ml, 2785 ± 432 ng/ml,
respectively, vs. 4134 ± 753 ng/ml in the control)
(Fig. 3f–h). However, we also observed a significant
drop in 6-keto-PGF1α plasma concentration in mice
treated with both docetaxel and 1,4-DMP (70.36 vs.
130.7 pg/ml, p < 0.05) (Fig. 3e).
Toxicity of the combined treatment of prostate cancer
comprising simultaneous application of 1,4-DMP and
docetaxel
In the control and 1,4-DMP-treated groups of animals,
there were no cases of deaths recorded. On the contrary,
administration of docetaxel resulted in 3 incidences of
treatment-related deaths (effect was not statistically
Fig. 3 The influence of the combined treatment comprising the use of docetaxel (DTX) and 1,4-DMP on platelet morphology and activity in BALB/c
Nude mice bearing PC-3M-luc2 tumors. a Platelet count; b platelet crit (PCT); c mean platelet volume (MPV); d platelet distribution width (PDW) deter-
mined on the last day of the experiment (day 46). Plasma concentration of: e 6-keto-prostaglandin F1α (6-keto-PGF1α) (*p < 0.05 vs. control and 1,4-
DMP); f thromboxane B2 (TXB2) (*p < 0.05 vs. control and 1,4-DMP); g soluble P-selectin (*p < 0.05 vs. control and 1,4-DMP); and h von Willebrand Factor
(vWF) (*p < 0.05 vs. control and 1,4-DMP), determined on the last day of the experiment (day 46). All data are presented as mean ± SD values
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significant). Surprisingly, docetaxel-induced toxicity was
lowered when cytotoxic drug was given simultaneously
with 1,4-DMP. In case of animals treated with the com-
bined regimen, only 1 incidence of death was recorded
(Fig. 4a). Regardless of the treatment applied, the body
weight of all tumor-bearing BALB/c Nude mice was de-
creasing throughout the study with the most prominent
body loss observed among control and 1,4-DMP-treated
animals (approx. 10–12% body weight loss). Among the
mice treated with docetaxel, a reduced body loss was ob-
served (approx. 6% body weight loss), which was nearly
abolished among animals treated with the combined
treatment (approx. 3% body weight loss) (Fig. 4b).
The analysis of blood morphology of the treated ani-
mals revealed that similar to the platelet count described
above, red blood cell count was lower in mice receiving
docetaxel alone (8.30 ± 0.8 × 106 vs. 9.1 ± 0.2 × 106).
However, in contrast to platelet count, red blood cell
count was not restored when docetaxel was adminis-
tered simultaneously with 1,4-DMP (8.4 ± 0.6 × 106) and
corresponded to non-significant change in hemoglobin
content that was observed in mice given docetaxel either
alone or in combination with 1,4-DMP (14.17 ± 1.3 g/dl
and 14.34 ± 0.9 g/dl vs. 14.81 ± 2.2 g/dl in the control).
Blood biochemistry analysis revealed that in groups re-
ceiving docetaxel, levels of plasma concentrations for
creatinine (5.7 ± 2.2 vs. 7.59 ± 2.3 μmol/l in the control)
and urea (6.98 ± 1.3 vs. 7.33 ± 1.1 mmol/l in the control)
were not significantly changed. However, when docetaxel
was concurrently administered with 1,4-DMP, it resulted
in a significantly lowered creatinine (4.99 ± 1.5 μmol/l, p
< 0.05 vs. control and 1,4-DMP-treated group) and urea
(5.67 ± 0.9 mmol/l, p < 0.05 vs. control and 1,4-DMP-
treated group) concentrations (Fig. 4e–f ).
Fig. 4 Toxicity of the combined treatment of prostate cancer comprising simultaneous application of 1,4-DMP and docetaxel (DTX). a Survival of
BALB/c Nude mice bearing PC-3 M-luc2 tumors, treated with docetaxel (DTX) and 1,4-DMP either alone or in combination. b Body weight of
BALB/c Nude mice bearing PC-3M-luc2 tumors, treated with docetaxel (DTX) and 1,4-DMP either alone or in combination. In graphs a and b, days
of drug administration are indicated with gray arrows for docetaxel (DTX) and dotted arrow for 1,4-DMP. c Red blood cell (RBC) count (*p < 0.05
vs. 14-DMP; **p < 0.05 vs. control and 1,4-DMP); and d hemoglobin concentration in blood samples taken from BALB/c Nude mice bearing PC-
3M-luc2 tumors on the last day of the experiment (day 46). Plasma concentrations of: e creatinine (*p < 0.05 vs. control and 1,4-DMP) and f urea
(*p < 0.05 vs. control and 1,4-DMP) determined for plasma samples obtained from BALB/c Nude mice bearing PC-3M-luc2 tumors on the last day
of the experiment (day 46). The activity of: g lactate dehydrogenase (LDH) (*p < 0.05 vs. control, DTX and 1,4-DMP); h aspartate aminotransferase
(AST) (*p < 0.05 vs. control, DTX and 1,4-DMP); and i alanine aminotransferase (ALT) (*p < 0.05 vs. control and 1,4-DMP) determined in blood
plasma samples obtained from BALB/c Nude mice bearing PC-3 M-luc2 tumors on the last day of the experiment (day 46). All data are presented
as mean ± SD values
Denslow et al. BMC Cancer  (2017) 17:177 Page 8 of 12
On the contrary, as it was determined for the blood
plasma samples taken from the treated mice bearing PC-
3M-luc2 tumors, administration of docetaxel had no influ-
ence on the activity of lactate dehydrogenase (LDH) (887.1
± 251.5 vs. 929.6 ± 202.5 U/l in the control, Fig. 4g) while
resulted in a slightly increased activity of aspartate amino-
transferase (AST) (209.1 ± 62.4 vs. 178.3 ± 51.7 U/l in the
control) and alanine aminotransferase (ALT) (82.72 ± 31.8
vs. 75.23 ± 34.1 U/l in the control group) (Fig. 4h and i).
However, when docetaxel was given simultaneously with
1,4-DMP to mice, significantly lower activity of all studied
liver enzymes was observed (LDH: 494.2 ± 73.9 U/l; AST:
96.36 ± 22.6 U/l; for both enzymes p < 0.05 vs. control, do-
cetaxel and 1,4-DMP-treated group; ALT: 36.16 ± 10.9 U/l,
p < 0.05 vs. control and DTX-treated group) (Fig. 4g–i).
Discussion
1-MNA is an endogenous metabolite of NA that was previ-
ously shown to possess significant anti-inflammatory and
anti-thrombotic activity [17, 18]. 1-MNA is synthetized by
nicotinamide N-methyltransferase (NMMT), an enzyme
expressed primarily in liver cells where it participates in
methylation of NA and other pyridine compounds [24].
Concurrently, the expression of NMMT was reported in
multiple types of cancer in which it was associated with
tumor-promoting activity [25–27] that could be further at-
tributed to 1-MNA [28]. On the contrary, some of the pub-
lished reports show the beneficial correlation between
NMMT expression and cancer survival [29, 30]. Along the
lines with such data in a recently published study, we have
shown that exogenous 1-MNA does not enhance the
growth of cancer cells neither in vitro nor in vivo but, in
contrary, may possess antimetastatic activity, most likely
resulting from its PGI2-releasing capacity. We have also
shown that 1,4-DMP, a structural analog of 1-MNA, pos-
sesses similar antimetastatic activity; however, both com-
pounds seemed to have different mechanisms of action that
ultimately resulted in platelet-dependent metastasis inhib-
ition. Importantly, pyridine compounds, but particularly
1,4-DMP, when given in a combination with cyclophospha-
mide contributed to its anticancer activity enhancing both
antitumor and antimetastatic activity of cytostatic drug
[21]. Referred studies were, however, carried out exclusively
in the mouse model of breast cancer, and the report did
not mention any activity of 1-MNA or 1,4-DMP in other
types of malignant tumors or with different anticancer
agents.
In the present work, we investigated the activity of both
compounds in the model of TRAMP mice that spontan-
eously develop prostate tumors. Similar to our previously
reported studies [21], both compounds, when adminis-
trated alone to mice developing prostate tumors, revealed
no significant anticancer activity; however, to some extent
these compounds delayed the disease onset (Fig. 1a–c).
Such a delayed disease onset might be attributed to the
prostacyclin-dependent activity of the compounds, as
prostacyclin was shown to inhibit lung tumor develop-
ment in PPARγ-dependent mechanism [31] that was also
shown to be involved in tumor growth arrest in prostate
tumors [32, 33]. Lack of the significant tumor preventing
activity of both pyridine compounds while being somehow
disappointing in terms of the possible application of 1-
MNA, and its analog in the prevention of prostate cancer,
is important for their implementation in anticancer treat-
ments, in general, as once again we demonstrated that
neither 1-MNA nor 1,4-DMP promoted the growth of
solid tumors. On the contrary, we have not observed any
antimetastatic activity of neither of the studied com-
pounds. In contrast, among 1-MNA-treated animals, we
even observed a slight increase of metastases frequency
(Fig. 1c and d). Such a surprising result might be the con-
sequence of prostacyclin-related inhibition of natural killer
cells [34] that, in turn, was shown to stimulate prostate
tumor metastasis [35]. Another explanation of the ob-
served limited antimetastatic activity of both 1-MNA and
1,4-DMP might be associated with previously reported re-
lationship between thrombin generation and the growth
and metastasis of prostate tumors in TRAMP mice [36].
Possibly, thrombin as a potent coagulation and platelet ac-
tivator that was proven to facilitate metastasis [37] coun-
teracts a possible antiplatelet activity of pyridine
compounds in this model. Importantly, in this study, we
noted that during the prostate tumor development, TGF-
β1 plasma concentration in TRAMP mice increased
(Fig. 1p), which remains consistent with the previous re-
ports indicating the usefulness of this molecule as a prog-
nostic factor in prostate tumors [38].
When investigating the anticancer activity of therapeutic
regimen including simultaneous use of docetaxel and 1,4-
DMP (that seemed to be more potent in the model of pros-
tate tumor as compared with 1-MNA) in the therapy of
metastatic human prostate cancer PC-3M-luc2, we ob-
served 60% enhancement of the antitumor activity of doce-
taxel given alone (Fig. 2c) and complete abolition of
metastases formation (Table 3) in mice treated with doce-
taxel administrated with 1,4-DMP. These results confirm
that 1,4-DMP may promote anticancer activity of various
cytotoxic drugs. Beneficial therapy outcome was also
reflected in the decreased plasma level of TGFβ-1, a mol-
ecule often acknowledged as a prognostic marker in pros-
tate cancer (Fig. 2i).
TGF-β1 is commonly recognized as a molecule inducing
epithelial-to-mesenchymal transition (EMT) in tumor-
forming cells. EMT is a phenomenon in result of which
non-invasive tumor cells of epithelial phenotype acquire
mesenchymal properties and become able to migrate and
invade distant tissues [39]. Therefore, in our study, lower
plasma concentration of TGF-β1, and by implication lower
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metastatic capacity, was associated with higher expression
ratio of E-cadherin to N-cadherin (Fig. 2f), cell adhesion
molecules commonly accepted as important markers of
EMT in cancer cells, including those of prostate origin [40].
Lower metastatic capacity of tumor-forming cells was add-
itionally accompanied by the lower level of short E-
cadherin fragments (40 kDa) observed in the tumor mass
of mice lacking metastases. Such short intracellular protein
fragments arise because of full-length E-cadherin cleavage
resulting in the release into extracellular matrix and next to
bloodstream of 80 kDa E-cadherin extracellular domain
[41]. Indeed, 80 kDa fragments identified in metastatic sites
or serum were previously discussed as potential prostate
cancer progression markers [42, 43]. Accordingly, in our
study, we observed that 40 kDa intracellular domain of E-
cadherin was abundant in tumor mass isolated from mice
bearing PC-3M-luc2 tumors diagnosed with metastases
(Fig. 2g). Finally, the prominent efficacy of the combined
treatment comprising the use of docetaxel and 1,4-DMP is
additionally confirmed by the decreased expression of
VEGFR-1 (Fig. 2h), another prognostic marker that has
been previously linked to enhanced metastatic potential of
prostate tumors [44].
We have previously shown that observed enhanced anti-
tumor and antimetastatic activity of cytotoxic drugs when
in a combination with 1,4-DMP might be a result of anti-
platelet activity of the latter compound [21]. Platelets, in
turn, contribute to metastases formation by several mech-
anisms as comprehensively reviewed in the literature [45,
46]. To confirm that increased anticancer efficacy of doce-
taxel observed when cytotoxic drug was given with 1,4-
DMP was associated with diminished platelets activity, we
have analyzed morphological and biochemical parameters
reflecting platelet activation status. In this regard, in mice
receiving the studied combined treatment, we observed
lowered values of mean platelet volume and PDW
(Fig. 3a–d) that may suggest decreased platelet activity
[47, 48]. Additionally, in mice treated with docetaxel and
1,4-DMP, we also noted a marked reduction in plasma
concentrations of TXB2, vWF and soluble P-selectin
(Fig. 3e–h), constituting biochemical markers, further
confirming diminished platelet activity.
Interestingly, increased antitumor activity of docetaxel
when administrated simultaneously with 1,4-DMP was
accompanied by its reduced toxicity manifested in the
decreased incidence of treatment-related deaths and im-
proved liver function (Fig. 4). Although we are currently
investigating these phenomena, our initial results indi-
cate that the observed protective activity of 1,4-DMP
may involve acetylcholinesterase and consequently
histamine-dependent pathways. It seems possible that in
response to the treatment with 1,4-DMP, the level of his-
tamine is increased that, in turn, may prevent liver injury
[49]. This novel and unexpected feature of the 1,4-DMP
treatment might not only be of a great value for possible
improvement of side effects in patients undergoing
chemotherapy, but may also allow to increase dosages in
patients with drug-resistant tumors to induce desired re-
sponse while maintaining acceptable treatment toxicity.
Conclusions
The results of the presented study prove that neither 1-
MNA nor 1,4-DMP when administrated alone do not influ-
ence the development and growth of the primary prostate
tumors supporting our previous findings in the murine
model of metastatic breast cancer. However, pyridine com-
pounds, such as 1,4-DMP, may beneficially influence the
antitumor and antimetastatic activity of docetaxel and add-
itionally limit the side effects accompanying chemotherapy.
Such findings allow us to believe that pyridine compound
endowed with PGI2 releasing properties [18, 20] may be-
come a promising agent for the adjuvant therapy of meta-
static cancer.
Additional file
Additional file 1: Figure S1. Changes in blood morphology and TGF-
β1 plasma concentration in TRAMP mice over time. Analysis were carried
out on blood samples taken on days 87, 122, 213 of the experiment and
during the necropsy of the animals: a platelet count (*p < 0.05 vs. control
D213, **p < 0.05 vs. 1,4-DMP D122); b mean platelet volume (MPV); c
platelet distribution width (PDW) (*p < 0.05 vs. Control D87, D122, D213;
**p < 0.05 vs. 1,4-DMP D87, D122); d red blood cell count (*p < 0.05 vs.
Control D87, D213, ** p < 0.05 vs. 1-MNA D87, ***p < 0.05 vs. 1,4-DMP
D87, D213); e lymphocyte count (*p < 0.05 vs. Control D87; **p < 0.05 vs.
1,4-DMP D87, D213); f monocyte count; g granulocyte count and h TGF-
β1 determined by ELISA (*p < 0.05 vs. Control D122, D213’ **p < 0.05 vs.
1-MNA D87, D213; ***p < 0.05 vs. 1,4-DMP D87, D213). All data are pre-
sented as mean ± SD. Data significantly different (p < 0.05) are marked
with stars. (TIFF 888 kb)
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inhibition; TNF-α: Tumor necrosis factor α; TV: Tumor volume;
TXB2: Thromboxane B2; VEGFR-1: Vascular endothelial growth factor receptor
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